Celltheon Corporation Revenue and Competitors

About Us: Located in the San Francisco Bay Area, Celltheon has been developing Cell Engineering technologies since 2012. Celltheon has patents, granted and pending, for its CHOK-1 derived SUPERCELL™ cell line and its unique DNA and RNA vector elements that are applicable for recombinant biotherapeutics such as Mabs, Difficult to Express Proteins (DEP) as well as for CAR-T, Gene Therapy and Cell Factories applications. Serving the Biotherapeutics Industry with Innovation & Dedication The CELLTHEON SMART™ Platform has been used to date in 60+ biotherapeutics for oncology, neurobiology and RA programs. In 2018 Celltheon formed strategic partnerships with industry leading companies to offer end-to-end cDNA to manufacturing solutions: scale-up process equipment, cell culture media and analytical screening tools for developing process based on Quality-By-Design (QBD). Combined with our industry leading Celltheon SMARTTM Platform and our deep knowhow, we provide Cell Line and Process Development services to make your most difficult to express therapeutic proteins commercially viable: • Antibody fragments • Difficult to express proteins • Fc-fusion proteins • mAbs CELLTHEON SMART™ PLATFORM  Reduces timelines  Lowers costs  Increases efficiencies  Ensures consistent product quality  Improves and accelerates decision-making CELLTHEON TECHNOLOGY HIGHLIGHTS  CELLTHEON SMART™ Platform enables commercial viability of Hard to Express Proteins  Celltheon SUPERCELL™ metabolic profile optimal for CQAs  CT-STABILIZER™ element results in clones with high generational stability (>120)  CT-STABILIZER™ element results in Qp as high as 60 pg/cell/day and robust/repeatable processes  CT-STABILIZER™ element results in high number of high-expressing clones  Provides robust & repeatable cDNA to scale-up workflow  Built in Quality By Design gives consistently high titer clones  CELLTHEON’s consistent CQAs at every scale gives you confidence in the success of your program